Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.43 |
| ▸ | CA1 | P00915 | 9/20 | 0.43 |
| ▸ | CA12 | O43570 | 8/20 | 0.39 |
| ▸ | CA9 | Q16790 | 8/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | CFB | P00751 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31145173 | 1.00 | CA2 (0.43) | CA2CA1CA12CA9CA14 | |
| SCHEMBL29324915 | 1.00 | CA2 (0.43) | CA2CA1CA12CA9CA14 | |
| SCHEMBL29324920 | 0.87 | DRD2 (0.44) | ALDH1A1CREBBP | |
| SCHEMBL30470852 | 0.87 | DRD2 (0.44) | ALDH1A1CREBBP | |
| SCHEMBL29081277 | 0.87 | DRD2 (0.44) | ALDH1A1CREBBP | |
| SCHEMBL29081275 | 0.87 | DRD2 (0.44) | ALDH1A1CREBBP | |
| SCHEMBL31145154 | 0.84 | CREBBP (0.38) | ALDH1A1CFBCREBBP | |
| SCHEMBL29081967 | 0.84 | CREBBP (0.38) | ALDH1A1CFBCREBBP | |
| SCHEMBL24363746 | 0.82 | CA2 (0.41) | CA2CA1CA12CA9CA14 | |
| SCHEMBL29082023 | 0.82 | CA2 (0.41) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | CA2 369/4885CA1 701/4885CA12 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.